Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.32
-0.1200-4.92%
Volume:523.53K
Turnover:1.22M
Market Cap:278.40M
PE:-2.20
High:2.45
Open:2.42
Low:2.28
Close:2.44
52wk High:3.23
52wk Low:0.9401
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.70
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.81
PE(LYR):-2.02

Loading ...

Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)

TIPRANKS
·
Jun 06

Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline

TIPRANKS
·
Jun 05

Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability

TIPRANKS
·
Jun 05

Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen

Reuters
·
Jun 04

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04

Fate Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Jun 04

Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan

Reuters
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 03

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo

Reuters
·
Jun 01

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

GlobeNewswire
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23

Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves

TIPRANKS
·
May 22

Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases

THOMSON REUTERS
·
May 21

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

GlobeNewswire
·
May 21

Fate Therapeutics assumed with a Buy at Jefferies

TIPRANKS
·
May 20

Wells Fargo Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
May 14

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

TIPRANKS
·
May 13